EE9800277A - 4-Aminopyrimidine derivatives, drugs containing these compounds, their use and a process for their preparation - Google Patents
4-Aminopyrimidine derivatives, drugs containing these compounds, their use and a process for their preparationInfo
- Publication number
- EE9800277A EE9800277A EE9800277A EE9800277A EE9800277A EE 9800277 A EE9800277 A EE 9800277A EE 9800277 A EE9800277 A EE 9800277A EE 9800277 A EE9800277 A EE 9800277A EE 9800277 A EE9800277 A EE 9800277A
- Authority
- EE
- Estonia
- Prior art keywords
- compounds
- preparation
- drugs containing
- aminopyrimidine derivatives
- aminopyrimidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1996108631 DE19608631A1 (en) | 1996-03-06 | 1996-03-06 | New (heterocyclyl- pyrimidino or -pyrido)fused pyrimidine derivatives |
DE19629652A DE19629652A1 (en) | 1996-03-06 | 1996-07-23 | 4-Amino-pyrimidine derivatives, medicaments containing these compounds, their use and processes for their preparation |
PCT/EP1997/001057 WO1997032881A1 (en) | 1996-03-06 | 1997-03-03 | 4-amino pyrimidine derivates, medicaments containing these compounds, their use and process for their production |
Publications (1)
Publication Number | Publication Date |
---|---|
EE9800277A true EE9800277A (en) | 1999-02-15 |
Family
ID=26023531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EE9800277A EE9800277A (en) | 1996-03-06 | 1997-03-03 | 4-Aminopyrimidine derivatives, drugs containing these compounds, their use and a process for their preparation |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP0885226A1 (en) |
JP (1) | JP2000506847A (en) |
KR (1) | KR19990087550A (en) |
CN (1) | CN1212695A (en) |
AU (1) | AU710274B2 (en) |
BG (1) | BG102708A (en) |
BR (1) | BR9708312A (en) |
CA (1) | CA2243994A1 (en) |
CZ (1) | CZ281798A3 (en) |
DE (1) | DE19629652A1 (en) |
EE (1) | EE9800277A (en) |
HU (1) | HUP9901820A3 (en) |
IL (1) | IL125404A0 (en) |
NO (1) | NO984084L (en) |
NZ (1) | NZ331546A (en) |
PL (1) | PL328771A1 (en) |
SK (1) | SK120598A3 (en) |
TR (1) | TR199801749T2 (en) |
WO (1) | WO1997032881A1 (en) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR199801530T2 (en) | 1996-02-13 | 1998-11-23 | Zeneca Limited | Quinazoline derivatives as VEGF inhibitors. |
PT885198E (en) | 1996-03-05 | 2002-06-28 | Astrazeneca Ab | 4-ANYLINOQUINAZOLINE DERIVATIVES |
EP1396489A1 (en) * | 1999-01-27 | 2004-03-10 | Pfizer Products Inc. | Heteroaromatic bicyclic derivatives useful as anticancer agents |
UA71945C2 (en) * | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
UA72946C2 (en) | 1999-11-05 | 2005-05-16 | Астразенека Аб | Quinasoline derivatives as inhibitors of vascular endothelial growth factor (vegf) |
BRPI0411608A (en) | 2003-06-24 | 2006-08-08 | Neurosearch As | 8-aza-bicyclo [3.2.1] octane derivative, pharmaceutical composition, use of the compound, and method of treating, preventing or alleviating a disease, disorder or condition of a living animal organism |
MX2007010068A (en) * | 2005-02-16 | 2007-10-10 | Schering Corp | Piperazine-piperidines with cxcr3 antagonist activity. |
EP2349235A1 (en) | 2008-11-07 | 2011-08-03 | Triact Therapeutics, Inc. | Use of catecholic butane derivatives in cancer therapy |
CA2745041C (en) * | 2008-12-01 | 2017-08-22 | Kai Schiemann | 2, 5-diamino-substituted pyrido [4, 3-d] pyrimidines as autotaxin inhibitors against cancer |
US20120189641A1 (en) | 2009-02-25 | 2012-07-26 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
JP2012519170A (en) | 2009-02-26 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ,エルエルシー | INSITU method for monitoring EMT status of tumor cells in vivo |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010099364A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010099363A1 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010107968A1 (en) | 2009-03-18 | 2010-09-23 | Osi Pharmaceuticals, Inc. | Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor |
JP2013510564A (en) | 2009-11-13 | 2013-03-28 | パンガエア ビオテック、ソシエダッド、リミターダ | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
EP2468883A1 (en) | 2010-12-22 | 2012-06-27 | Pangaea Biotech S.L. | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
US9134297B2 (en) | 2011-01-11 | 2015-09-15 | Icahn School Of Medicine At Mount Sinai | Method and compositions for treating cancer and related methods |
EP2492688A1 (en) | 2011-02-23 | 2012-08-29 | Pangaea Biotech, S.A. | Molecular biomarkers for predicting response to antitumor treatment in lung cancer |
WO2012129145A1 (en) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Nscle combination therapy |
WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
CA2845179A1 (en) | 2011-08-31 | 2013-03-07 | Genentech, Inc. | Diagnostic markers |
JP2014531213A (en) | 2011-09-30 | 2014-11-27 | ジェネンテック, インコーポレイテッド | Diagnostic methylation markers for epithelial or mesenchymal phenotype and response to EGFR kinase inhibitors in tumors or tumor cells |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
WO2013190089A1 (en) | 2012-06-21 | 2013-12-27 | Pangaea Biotech, S.L. | Molecular biomarkers for predicting outcome in lung cancer |
EP2961412A4 (en) | 2013-02-26 | 2016-11-09 | Triact Therapeutics Inc | Cancer therapy |
WO2014147246A1 (en) | 2013-03-21 | 2014-09-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression |
WO2015035410A1 (en) | 2013-09-09 | 2015-03-12 | Triact Therapeutic, Inc. | Cancer therapy |
WO2015156674A2 (en) | 2014-04-10 | 2015-10-15 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
AU2015371312B2 (en) | 2014-12-24 | 2022-01-27 | Genentech, Inc. | Therapeutic, diagnostic and prognostic methods for cancer of the bladder |
ES2894255T3 (en) | 2016-12-22 | 2022-02-14 | Amgen Inc | Benzoisothiazole derivatives, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as KRAS G12C inhibitors to treat lung cancer pancreatic or colorectal |
JOP20190272A1 (en) | 2017-05-22 | 2019-11-21 | Amgen Inc | Kras g12c inhibitors and methods of using the same |
UY37870A (en) | 2017-09-08 | 2019-03-29 | Amgen Inc | KRAS G12C INHIBITORS AND METHODS TO USE THEM FIELD OF THE INVENTION |
US11090304B2 (en) | 2018-05-04 | 2021-08-17 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
CA3099118A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
AU2019265822A1 (en) | 2018-05-10 | 2020-11-19 | Amgen Inc. | KRAS G12C inhibitors for the treatment of cancer |
MA52765A (en) | 2018-06-01 | 2021-04-14 | Amgen Inc | KRAS G12C INHIBITORS AND THEIR PROCEDURES FOR USE |
MA52780A (en) | 2018-06-11 | 2021-04-14 | Amgen Inc | KRAS G12C INHIBITORS FOR CANCER TREATMENT |
AU2019336588B2 (en) | 2018-06-12 | 2022-07-28 | Amgen Inc. | KRAS G12C inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer |
CA3115038A1 (en) | 2018-10-04 | 2020-04-09 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Egfr inhibitors for treating keratodermas |
JP2020090482A (en) | 2018-11-16 | 2020-06-11 | アムジエン・インコーポレーテツド | Improved synthesis of key intermediate of kras g12c inhibitor compound |
JP7377679B2 (en) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer |
MX2021005700A (en) | 2018-11-19 | 2021-07-07 | Amgen Inc | Kras g12c inhibitors and methods of using the same. |
MX2021007156A (en) | 2018-12-20 | 2021-08-16 | Amgen Inc | Kif18a inhibitors. |
MX2021007158A (en) | 2018-12-20 | 2021-08-16 | Amgen Inc | Heteroaryl amides useful as kif18a inhibitors. |
WO2020132653A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
EP3897855B1 (en) | 2018-12-20 | 2023-06-07 | Amgen Inc. | Kif18a inhibitors |
SG11202109036WA (en) | 2019-03-01 | 2021-09-29 | Revolution Medicines Inc | Bicyclic heteroaryl compounds and uses thereof |
AU2020232616A1 (en) | 2019-03-01 | 2021-09-09 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
CN114144414A (en) | 2019-05-21 | 2022-03-04 | 美国安进公司 | Solid state form |
MX2022001295A (en) | 2019-08-02 | 2022-02-22 | Amgen Inc | Kif18a inhibitors. |
MX2022001296A (en) | 2019-08-02 | 2022-02-22 | Amgen Inc | Kif18a inhibitors. |
EP4007638A1 (en) | 2019-08-02 | 2022-06-08 | Amgen Inc. | Pyridine derivatives as kif18a inhibitors |
AU2020324963A1 (en) | 2019-08-02 | 2022-02-24 | Amgen Inc. | KIF18A inhibitors |
WO2021081212A1 (en) | 2019-10-24 | 2021-04-29 | Amgen Inc. | Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer |
CR20220240A (en) | 2019-11-04 | 2022-08-03 | Revolution Medicines Inc | Ras inhibitors |
TW202132314A (en) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ras inhibitors |
JP2022553858A (en) | 2019-11-04 | 2022-12-26 | レボリューション メディシンズ インコーポレイテッド | RAS inhibitor |
CA3156359A1 (en) | 2019-11-08 | 2021-05-14 | Adrian Liam Gill | Bicyclic heteroaryl compounds and uses thereof |
WO2021097207A1 (en) | 2019-11-14 | 2021-05-20 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
US20230192681A1 (en) | 2019-11-14 | 2023-06-22 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
EP4065231A1 (en) | 2019-11-27 | 2022-10-05 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
TW202140011A (en) | 2020-01-07 | 2021-11-01 | 美商銳新醫藥公司 | Shp2 inhibitor dosing and methods of treating cancer |
KR20230042600A (en) | 2020-06-18 | 2023-03-28 | 레볼루션 메디슨즈, 인크. | Methods of Delaying, Preventing, and Treating Acquired Resistance to RAS Inhibitors |
AU2021344830A1 (en) | 2020-09-03 | 2023-04-06 | Revolution Medicines, Inc. | Use of SOS1 inhibitors to treat malignancies with SHP2 mutations |
IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as ras inhibitors in the treatment of cancer |
JP2024501280A (en) | 2020-12-22 | 2024-01-11 | キル・レガー・セラピューティクス・インコーポレーテッド | SOS1 inhibitors and their uses |
CR20230570A (en) | 2021-05-05 | 2024-01-22 | Revolution Medicines Inc | Ras inhibitors |
AR125787A1 (en) | 2021-05-05 | 2023-08-16 | Revolution Medicines Inc | RAS INHIBITORS |
CN117500811A (en) | 2021-05-05 | 2024-02-02 | 锐新医药公司 | Covalent RAS inhibitors and uses thereof |
AR127308A1 (en) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | RAS INHIBITORS |
TW202340214A (en) | 2021-12-17 | 2023-10-16 | 美商健臻公司 | Pyrazolopyrazine compounds as shp2 inhibitors |
EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL112249A (en) * | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
DE4431867A1 (en) * | 1994-09-07 | 1996-03-14 | Thomae Gmbh Dr K | New 4-amino-pyrimido-pyrimidine derivs. |
-
1996
- 1996-07-23 DE DE19629652A patent/DE19629652A1/en not_active Ceased
-
1997
- 1997-03-03 BR BR9708312A patent/BR9708312A/en not_active IP Right Cessation
- 1997-03-03 SK SK1205-98A patent/SK120598A3/en unknown
- 1997-03-03 HU HU9901820A patent/HUP9901820A3/en unknown
- 1997-03-03 CA CA002243994A patent/CA2243994A1/en not_active Abandoned
- 1997-03-03 NZ NZ331546A patent/NZ331546A/en unknown
- 1997-03-03 CZ CZ982817A patent/CZ281798A3/en unknown
- 1997-03-03 CN CN97192787A patent/CN1212695A/en active Pending
- 1997-03-03 TR TR1998/01749T patent/TR199801749T2/en unknown
- 1997-03-03 EE EE9800277A patent/EE9800277A/en unknown
- 1997-03-03 EP EP97907066A patent/EP0885226A1/en not_active Ceased
- 1997-03-03 JP JP9531444A patent/JP2000506847A/en active Pending
- 1997-03-03 PL PL97328771A patent/PL328771A1/en unknown
- 1997-03-03 AU AU19251/97A patent/AU710274B2/en not_active Ceased
- 1997-03-03 KR KR1019980706987A patent/KR19990087550A/en not_active Application Discontinuation
- 1997-03-03 WO PCT/EP1997/001057 patent/WO1997032881A1/en not_active Application Discontinuation
- 1997-03-03 IL IL12540497A patent/IL125404A0/en unknown
-
1998
- 1998-08-20 BG BG102708A patent/BG102708A/en unknown
- 1998-09-04 NO NO984084A patent/NO984084L/en unknown
Also Published As
Publication number | Publication date |
---|---|
HUP9901820A2 (en) | 1999-09-28 |
CN1212695A (en) | 1999-03-31 |
NO984084D0 (en) | 1998-09-04 |
DE19629652A1 (en) | 1998-01-29 |
AU1925197A (en) | 1997-09-22 |
TR199801749T2 (en) | 1998-12-21 |
BG102708A (en) | 1999-09-30 |
AU710274B2 (en) | 1999-09-16 |
CA2243994A1 (en) | 1997-09-12 |
SK120598A3 (en) | 1999-06-11 |
EP0885226A1 (en) | 1998-12-23 |
JP2000506847A (en) | 2000-06-06 |
CZ281798A3 (en) | 1999-02-17 |
BR9708312A (en) | 1999-08-03 |
NO984084L (en) | 1998-09-04 |
PL328771A1 (en) | 1999-02-15 |
KR19990087550A (en) | 1999-12-27 |
NZ331546A (en) | 2000-03-27 |
HUP9901820A3 (en) | 2001-10-29 |
IL125404A0 (en) | 1999-03-12 |
WO1997032881A1 (en) | 1997-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE9800277A (en) | 4-Aminopyrimidine derivatives, drugs containing these compounds, their use and a process for their preparation | |
EE9500080A (en) | Erythromycin derivatives, a process for their preparation and a pharmaceutical composition containing them | |
EE200000168A (en) | Carboxamidothiazole derivatives, their preparation and pharmaceutical compositions containing them | |
EE200300300A (en) | Quinazoline derivatives, drugs containing these compounds, their use and a process for their preparation | |
EE04375B1 (en) | Modified amino acids, drugs containing these compounds, and process for their preparation | |
EE9700323A (en) | Taxoids, a process for their preparation and pharmaceutical compositions containing them | |
EE9800028A (en) | Iprotropium salts, pharmaceutical compositions containing them and their use | |
EE9700333A (en) | Substituted 4-phenylaminothiazoles, a process for their preparation and pharmaceutical compositions containing them | |
DE69833464D1 (en) | A pharmaceutical composition containing 2,3-diaryl-pyrazolo1,5-bPyridazine derivatives | |
HUP9901159A3 (en) | Substituted benzylaminopiperidine derivatives and use thereof, pharmaceutical compositions containing these compounds | |
EE04399B1 (en) | Spiroazabicyclic Heterocyclic Compounds, Process for their Preparation, Pharmaceutical Compositions Containing Them and Their Use in Therapy | |
DE59712959D1 (en) | ORAL PHARMACEUTICAL PREPARATION CONTAINING IBANDRONAT | |
EE200000707A (en) | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them | |
EE200100695A (en) | Bicyclic heterocyclic compounds, drugs containing these compounds, their use and methods for their preparation | |
HUP9901037A3 (en) | Piperazine derivatives,preparation and use thereof, pharmaceutical compositions containing these compounds | |
EE04282B1 (en) | Pyrazole Pyrimidines, Their Preparation and Use as a Pharmaceutical, and Composition Containing Them | |
FI972646A (en) | Piperazine derivatives, these compounds containing drugs, their use and process for their preparation | |
HUP9901096A3 (en) | Indole derivatives, preparation and use thereof, pharmaceutical composition containing these compounds | |
EE200200369A (en) | Substituted piperidines, drugs containing these compounds and methods for their preparation | |
EE9800302A (en) | Arylglycinamide derivatives, process for their preparation and use, and pharmaceutical preparation | |
HUP9900348A3 (en) | New oxazolidinone derivatives, preparation and use thereof and medicaments containing these compounds | |
EE03825B1 (en) | 2-Cyanoiminoimidazole derivatives, process for their preparation, use and pharmaceutical compositions | |
EE04348B1 (en) | Carbohydrate derivatives, a pharmaceutical composition containing them and their use | |
EE200100027A (en) | Organophosphorus compounds, their pharmaceutical preparation and their use | |
AU3166895A (en) | Condensed azepine derivatives, drugs containing these compounds and methods for preparing them |